Starpharma Holdings Ltd (ASX: SPL) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Starpharma Holdings Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $45.32 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 412.04 million
Earnings per share -0.022
Dividend per share N/A
Year To Date Return -29.41%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Starpharma Holdings Ltd (ASX: SPL)
    Latest News

    A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
    Healthcare Shares

    3 ASX healthcare shares up 10% to 22% on news

    These healthcare shares are catching the eye on Wednesday. But why?

    Read more »

    A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
    Share Gainers

    Why Delta Lithium, Liontown, Pact, and Starpharma shares are storming higher

    These ASX shares are rising despite the market weakness.

    Read more »

    A person with a round-mouthed expression clutches a device screen and looks shocked and surprised.
    Healthcare Shares

    Here's why the Starpharma share price just exploded 50%!

    This biotech is catching the eye of investors on Wednesday. But why?

    Read more »

    Health workers shake hands and congratulate each other on good news.
    Earnings Results

    4 ASX healthcare shares charging higher on positive earnings updates

    These ASX healthcare shares are recording strong share price gains today.

    Read more »

    A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
    Share Fallers

    Why IGO, Patriot Battery Metals, Silver Lake, and Starpharma shares are sinking today

    These ASX shares are starting the week in the red.

    Read more »

    A man slumps crankily over his morning coffee as it pours with rain outside.
    Healthcare Shares

    Why is this ASX All Ords share sinking 34% on Monday?

    Investors have been selling off this healthcare share due to some bad news.

    Read more »

    A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
    Share Fallers

    Why Legend Mining, Medibank, Starpharma, and Weebit Nano shares are sinking

    These ASX shares are having a tough time on Tuesday.

    Read more »

    a woman holds her hands up in delight as she sits in front of her lap
    Share Gainers

    Why AGL, Retail Food Group, Starpharma, and TPG shares are rising today

    These ASX shares have avoided the market selloff...

    Read more »

    three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
    Share Gainers

    Why Bendigo Bank, Block, Megaport, and Starpharma shares are rising today

    These ASX shares are on form on Tuesday...

    Read more »

    a woman holds a cup to her ear and leans in with a wide mouthed expression on her face as though she is listening to interesting and perhaps surprising information.
    52-Week Lows

    5 ASX shares trading near 52-week lows that insiders have been buying

    Insiders appear to believe these shares are trading at attractive prices.

    Read more »

    A man looks down with fright as he falls towards the ground.
    Share Fallers

    3 ASX All Ords shares tumbling into the weekend

    This trio of All Ords shares has had a shocker today...

    Read more »

    Rising arrow on a blue graph symbolising a rising share price.
    Healthcare Shares

    Starphama share price lunges 5% on product relaunch

    Early support for Starphama on Thursday has it off to a great start.

    Read more »

    Frequently Asked Questions

    No, Starpharma does not pay dividends at this time.

    Starpharma listed on the ASX on 28 September 2000.

    SPL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Starpharma Holdings Ltd

    Starpharma Holdings Ltd (ASX: SPL) is an Australian biotechnology company involved in the development of dendrimer products for pharmaceutical, life science, and other applications.

    Dendrimers are synthetically manufactured, nanoscale molecules, particularly useful to the pharmaceutical industry for their unique properties as carriers of other molecular structures.

    Starpharma describes itself as a world leader in the field. The company is developing programs for drug delivery applications, the treatment of respiratory viruses, and its VivaGel product.

    VivaGel can be used for the management and prevention of bacterial vaginosis and as a coating for condoms. The company's VIRALEZE product is an antiviral nasal spray approved for use in many countries, including Europe and the UK.

    SPL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    29 May 2024 $0.11 $-0.01 -8.33% 334,199 $0.12 $0.12 $0.11
    28 May 2024 $0.12 $0.00 0.00% 214,297 $0.12 $0.12 $0.12
    27 May 2024 $0.12 $0.01 9.09% 1,227,868 $0.12 $0.13 $0.12
    24 May 2024 $0.11 $-0.01 -8.70% 565,381 $0.12 $0.12 $0.11
    23 May 2024 $0.12 $0.00 0.00% 121,442 $0.12 $0.12 $0.12
    22 May 2024 $0.12 $0.01 9.09% 213,538 $0.11 $0.12 $0.11
    21 May 2024 $0.11 $-0.01 -8.70% 175,942 $0.12 $0.12 $0.11
    20 May 2024 $0.12 $0.01 9.09% 289,776 $0.12 $0.12 $0.11
    17 May 2024 $0.11 $-0.01 -8.70% 620,903 $0.12 $0.12 $0.11
    16 May 2024 $0.12 $0.00 0.00% 116,204 $0.12 $0.12 $0.12
    15 May 2024 $0.12 $0.00 0.00% 155,521 $0.12 $0.13 $0.12
    14 May 2024 $0.12 $0.00 0.00% 470,126 $0.12 $0.13 $0.12
    13 May 2024 $0.12 $0.00 0.00% 9,119 $0.12 $0.13 $0.12
    10 May 2024 $0.12 $-0.01 -8.00% 647,310 $0.13 $0.13 $0.12
    09 May 2024 $0.13 $0.00 0.00% 417,600 $0.12 $0.13 $0.12
    08 May 2024 $0.13 $0.01 8.33% 801,047 $0.12 $0.13 $0.12
    07 May 2024 $0.12 $-0.01 -8.00% 289,983 $0.12 $0.13 $0.12
    06 May 2024 $0.13 $0.01 8.33% 76,190 $0.12 $0.13 $0.12
    03 May 2024 $0.12 $0.00 0.00% 1,162,480 $0.12 $0.13 $0.11
    02 May 2024 $0.12 $0.00 0.00% 2,161,871 $0.12 $0.12 $0.12
    01 May 2024 $0.12 $-0.01 -8.00% 1,564,600 $0.13 $0.13 $0.12
    30 Apr 2024 $0.13 $-0.01 -7.41% 1,122,960 $0.13 $0.14 $0.13

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    15 Apr 2024 Robert Thomas Buy 100,000 $13,000
    On-market trade.
    12 Apr 2024 Russell Basser Buy 71,428 $10,002
    On-market trade.
    10 Apr 2024 Robert Thomas Buy 250,000 $43,424
    On-market trade.
    08 Dec 2023 Jacinth (Jackie) Fairley Issued 667,441 $90,104
    Issue of securities. 6,432,648 Performance Rights
    06 Oct 2023 Jacinth (Jackie) Fairley Expiry 514,918 $69,513
    As advised by the company. 5,765,207 Performance Rights, lapsed

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Robert Bain Thomas Non-Executive DirectorNon-Executive Chairman Dec 2013
    Mr Thomas has a background in financial services and capital markets and is a non-executive director of several Australian listed companies. Formerly Mr Thomas was a Partner of Potter Partners (now UBS) where he was also Head of Research. Mr Thomas is the former Chief Executive Officer (CEO) of County NatWest Securities and then became CEO and then Chairman of Citibank Corporate and Investment Bank in Australia. Mr Thomas has also held the position of Chairman at Australian Wealth Management Ltd (ultimately IOOF Ltd), TAL (Australia's life insurance company) and HeartWare International Inc, the global manufacturer of left ventricular assist heart pumps. Mr Thomas is currently a non-executive director of ASX-listed Biotron Limited and Clarity Pharmaceuticals Limited. He is member of Risk Committee.
    Ms Cheryl Ann Maley Chief Executive OfficerManaging Director Jan 2024
    Mrs Maley has pharmaceutical industry experience in range of therapeutic areas, including oncology, womens health, infectious diseases, immunology, cardiology, gastroenterology, dermatology and neuroscience. She has worked with GP, specialist, and hospital products and has experience as a commercial leader on global product development teams. Cheryl began her career in research at CSIRO before moving into sales and marketing roles at Servier Laboratories, Lederle Laboratories, and Wyeth Pharmaceuticals. She then moved into several leadership positions in business development, sales and marketing at Abbott Australia and, later, Abbott International. Her roles included Director of the Specialty Products Division in Australia, Director of the Global Strategic Initiatives, Immunology, in the US, and Director of Commercial Excellence During her nine-year career at Novartis, Cheryl held several senior leadership positions. Cheryl was Country Head and President of Novartis Philippines. Cheryl has most recently been serving as the Acting CEO and Strategic Advisor at Biointelect. Currently, Cheryl is also a Non-Executive Director of Clarity Pharmaceuticals (ASX:CU6).
    Mr David McIntyre Non-Executive Director Mar 2020
    Mr McIntyre has more than 20 years of executive experience including 18 years in the life sciences sector, having held various C-suite level roles at Tessa Therapeutics, Inc., AVITA Therapeutics, Inc., HeartWare International, Inc., and Braeburn, Inc. Mr McIntyre's experience also includes seven years as a Partner at Apple Tree Partners, a life science venture capital and growth equity fund, giving him knowledge of, and contacts in, the US pharma, medical device and biotech markets. During this time, Mr McIntyre served as a non-executive director of several US life science companies. Prior to entering life sciences, Mr McIntyre practiced as a senior attorney at Baker & McKenzie and KPMG specialising in M&A, initial public offerings, and corporate law and held various senior finance roles in both multinational companies and small growth companies. He is Chair of Risk Committee.
    Ms Lynda Cheng Non-Executive Director Aug 2021
    Ms Cheng has a background in finance with more than 25 years of experience as a finance executive including more than 15 years at Visy Industries/Pratt Holdings and 10 years in investment banking. She has commercial and international corporate expertise including experience in financial services, manufacturing, export finance, infrastructure, education as well as market entry, growth, and technology. Ms Cheng is currently Director of Corporate Development and Mergers & Acquisitions at Visy Industries / Pratt Holdings and has held various other roles in the group including CFO. Ms Cheng's earlier roles include as a lawyer at Blake Dawson, before moving into investment banking with J.P. Morgan in its Melbourne, Sydney, San Francisco, and New York offices. She is member of Risk Committee.
    Dr Jeff Davies Non-Executive Director Apr 2022
    Dr Davies is a former CSL executive with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at CSL for the Asia-Pacific region, and Global Head of Plasma Product Research and Development at CSL-Behring, Switzerland. As Executive Vice President & General Manager at CSL for the Asia-Pacific region, Dr Davies had overall P&L responsibility for the commercial and operational aspects of the business and oversaw the pharmaceutical, plasma, vaccine, and diagnostic businesses in Australia, New Zealand, China, and the broader Asia-Pacific region.
    Dr Russell Basser Non-Executive Director Feb 2023
    Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL. Dr Basser has expertise in international drug and vaccine development, having held multiple senior executive roles at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited/CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring/CSL Limited.
    Mr Justin Cahill Chief Financial OfficerCompany Secretary Apr 2023
    Justin Cahil Chief Financial Officer (CFO) and Company Secretary
    Justin Cahill Chief Financial OfficerCompany Secretary
    Tony Eglezos VP Business Development
    J R Paull VP Development & Regulatory Affairs

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 122,237,260 29.78%
    Jp Morgan Nominees Australia Pty Limited 37,825,457 9.21%
    Citicorp Nominees Pty Limited 29,722,931 7.24%
    BNP Paribas Noms Pty Ltd <DRP> 20,532,433 5.00%
    National Nominees Limited 5,752,680 1.40%
    Bnp Paribas Nominees Pty Ltd Acf Clearstream 5,064,744 1.23%
    T & N Argyrides Investments P/L <T & N Argyrides Pension A/C> 5,060,000 1.24%
    Mr Kingsley Bryan Bartholomew 3,427,025 0.83%
    Applecross Secretarial Services Pty Ltd <L Gorr Family A/C> 3,361,550 0.82%
    Ms Jacinth Fairley 3,252,386 0.79%
    BNP Paribas Nominees Pty Ltd <IN AU Noms Retail Client> DRP>>Agency Lending DRP A/C> 2,814,519 0.69%
    Mr Peter Murray Jackson DRP>>Agency Lending DRP A/C> 2,620,000 0.64%
    HSBC Custody Nominees (Australia) Limited A/C 2 2,564,149 0.62%
    Dollar Coin Investments Pty Ltd <Cousins Discretionary A/C> 2,007,501 0.49%
    Bell Potter Nominees Ltd 2,000,000 0.49%
    Evelyn Family Beneficiary Pty Ltd 1,679,537 0.41%
    Peppertree Custodian Services Pty Ltd <Mulcahy Superannuation> 1,644,450 0.40%
    Mr Nigel James Baade 1,629,725 0.40%
    Mr Thomas Harrington Mann 1,567,617 0.38%
    Mr David Michael Hosey and Mrs Andrea Jane Hosey 1,477,652 0.36%